Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | PTGFR | P43088 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3735391 | 0.86 | CRHR1 (0.42) | CRHR1P2RX3 | |
| SCHEMBL3759280 | 0.85 | CRHR1 (0.40) | CRHR1P2RX3 | |
| SCHEMBL4092611 | 0.82 | CRHR1 (0.37) | CRHR1P2RX7IDH1PTGFR | |
| SCHEMBL3808865 | 0.82 | CRHR1 (0.48) | CRHR1P2RX3P2RX7 | |
| SCHEMBL3751431 | 0.76 | CRHR1 (0.43) | CRHR1P2RX7 | |
| SCHEMBL2055965 | 0.76 | CRHR1 (0.60) | CRHR1P2RX7 | |
| SCHEMBL3737099 | 0.75 | CRHR1 (0.47) | CRHR1P2RX3 | |
| SCHEMBL3734189 | 0.74 | CRHR1 (0.42) | CRHR1P2RX3P2RX7 | |
| SCHEMBL3809137 | 0.74 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL3725597 | 0.73 | CRHR1 (0.40) | CRHR1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | CRHR1 1/4885P2RX3 70/4885P2RX7 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.